Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1175

Similar articles for PubMed (Select 19823051)

1.

Efficacy of human papillomavirus vaccines: a systematic quantitative review.

Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC, Zanini RR.

Int J Gynecol Cancer. 2009 Oct;19(7):1166-76. doi: 10.1111/IGC.0b013e3181a3d100. Review.

PMID:
19823051
2.

Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.

Schwarz TF.

Adv Ther. 2009 Nov;26(11):983-98. doi: 10.1007/s12325-009-0079-5. Epub 2009 Dec 18. Review.

PMID:
20024678
3.

Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.

Rambout L, Hopkins L, Hutton B, Fergusson D.

CMAJ. 2007 Aug 28;177(5):469-79. Epub 2007 Aug 1. Review.

4.

A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.

Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Maansson R, Lu S, Vuocolo S, Hesley TM, Saah A, Barr E, Haupt RM.

Cancer Prev Res (Phila). 2009 Oct;2(10):868-78. doi: 10.1158/1940-6207.CAPR-09-0031. Epub 2009 Sep 29.

5.

Evaluation of the interim analysis from the PATRICIA study group: efficacy of a vaccine against HPV 16 and 18.

Frederick PJ, Huh WK; PATRICIA Study Group.

Expert Rev Anticancer Ther. 2008 May;8(5):701-5. doi: 10.1586/14737140.8.5.701. Review. Erratum in: Expert Rev Anticancer Ther. 2008 Jun;8(6):1014.

PMID:
18471043
6.

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.

FUTURE II Study Group.

N Engl J Med. 2007 May 10;356(19):1915-27.

7.

A review of clinical trials of human papillomavirus prophylactic vaccines.

Schiller JT, Castellsagué X, Garland SM.

Vaccine. 2012 Nov 20;30 Suppl 5:F123-38. doi: 10.1016/j.vaccine.2012.04.108. Review.

PMID:
23199956
8.

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.

Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.

J Natl Cancer Inst. 2010 Mar 3;102(5):325-39. doi: 10.1093/jnci/djp534. Epub 2010 Feb 5.

9.

Human papillomavirus vaccine and cervical cancer prevention: practice and policy implications for pharmacists.

McIntosh J, Sturpe DA, Khanna N.

J Am Pharm Assoc (2003). 2008 Jan-Feb;48(1):e1-13; quiz e14-7. doi: 10.1331/JAPhA/2008.07032. Review.

PMID:
18192123
10.
11.

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.

FUTURE I/II Study Group, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Maansson R, Lu S, Vuocolo S, Hesley TM, Barr E, Haupt R.

BMJ. 2010 Jul 20;341:c3493. doi: 10.1136/bmj.c3493.

12.

[HPV vaccination: principles, results and future perspectives].

Rouzier R, Uzan C, Collinet P.

J Gynecol Obstet Biol Reprod (Paris). 2007 Feb;36(1):13-8. Epub 2007 Jan 17. Review. French.

13.

Quadrivalent human papillomavirus vaccine.

Barr E, Tamms G.

Clin Infect Dis. 2007 Sep 1;45(5):609-7. Epub 2007 Jul 25. Review.

14.

Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP).

MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24.

15.

Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health.

Harper DM.

Public Health Genomics. 2009;12(5-6):319-30. doi: 10.1159/000214922. Epub 2009 Aug 11. Review.

PMID:
19684444
16.

HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis.

La Torre G, de Waure C, Chiaradia G, Mannocci A, Ricciardi W.

Vaccine. 2007 Dec 5;25(50):8352-8. Epub 2007 Sep 29. Review.

PMID:
17996990
17.

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.

Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, Dubin G; HPV-010 Study Group.

Hum Vaccin. 2009 Oct;5(10):705-19. Epub 2009 Oct 14.

PMID:
19684472
18.

Safety, tolerability and side effects of human papillomavirus vaccines: a systematic quantitative review.

Gonçalves AK, Cobucci RN, Rodrigues HM, de Melo AG, Giraldo PC.

Braz J Infect Dis. 2014 Nov-Dec;18(6):651-9. doi: 10.1016/j.bjid.2014.02.005. Epub 2014 Apr 27. Review.

19.

[Diseases caused by human papilloma viruses].

Zollner U, Schwarz TF.

Dtsch Med Wochenschr. 2011 May;136(20):1067-72. doi: 10.1055/s-0031-1275845. Epub 2011 May 10. Review. German.

PMID:
21560109
20.

Human papillomavirus and vaccination in cervical cancer.

Wang KL.

Taiwan J Obstet Gynecol. 2007 Dec;46(4):352-62. doi: 10.1016/S1028-4559(08)60004-2. Review.

PMID:
18182340
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk